239
Participants
Start Date
August 31, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2027
Ustekinumab
The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
RECRUITING
Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Department of Gastroenterology, Seventh Medical Center of PLA Army General Hospital, Beijing
RECRUITING
Department of Gastroenterology, Chongqing Renji Hospital, University of Chinese Academy of Sciences, Chongqing
RECRUITING
Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou
RECRUITING
Department of Gastroenterology, Huai'an First People's Hospital, Huai'an
RECRUITING
Department of Gastroenterology, Second Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou
RECRUITING
Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Chongqing Renji Hospital, University of Chinese Academy of Sciences
OTHER_GOV
The First Affiliated Hospital of Zhejiang Chinese Medical University
OTHER
Seventh Medical Center of PLA Army General Hospital
OTHER
First People's Hospital of Hangzhou
OTHER
Yangzhou University
OTHER
Xian-Janssen Pharmaceutical Ltd.
INDUSTRY
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER